MétaCan
Menu
Back to cohort
Record W4405157039 · doi:10.1101/2024.12.07.627318

Lipid-based nanoparticles deliver mRNA to reverse the pathogenesis of lysosomal acid lipase deficiency in a preclinical model

2024· preprint· en· W4405157039 on OpenAlexafffund
Matthias Zadory, Elliot Lopez, Hamza Haddouch, Samuel Babity, Nastaran Rezaei, Fatma Moawad, Rita Maria Kenaan El Rahbani, Nemanja Vujić, Vincent Quoc‐Huy Trinh, Dagmar Kratky, Simon‐Pierre Gravel, Davide Brambilla

Bibliographic record

VenuebioRxiv (Cold Spring Harbor Laboratory) · 2024
Typepreprint
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCalcium signaling and nucleotide metabolism
Canadian institutionsInstitute for Research in Immunology and CancerUniversité de Montréal
FundersCanadian Institutes of Health ResearchNatural Sciences and Engineering Research Council of CanadaInstitut de Cardiologie de MontréalKarl-Franzens-Universität GrazUniversité de MontréalFonds de Recherche du Québec - SantéMedizinische Universität GrazAmt der Steiermärkischen LandesregierungCanada First Research Excellence FundAustrian Science Fund
KeywordsLipasePathogenesisMessenger RNAChemistryCell biologyBiochemistryMedicineEnzymeBiologyInternal medicineGene

Abstract

fetched live from OpenAlex

Abstract Lysosomal acid lipase (LAL) is the only known enzyme that degrades cholesteryl esters (CEs) and triglycerides (TGs) in the lysosomes. LAL deficiency (LAL-D) results in hepatosplenomegaly with extensive accumulation of CEs and TGs, and can in the most severe cases be a life-threatening condition in early infancy. Using messenger ribonucleic acid (mRNA) for protein replacement is an innovative approach for the treatment of genetic disorders, but is challenged by a safe and efficient mRNA delivery. Here, we generated a combinatorial library of lipid-based nanoparticles (LNPs) for mRNA delivery and screened it in vitro and in vivo, which yielded a new formulation with a superior potency than an FDA-approved nanoformulation. This formulation efficiently delivered LAL mRNA and restored LAL activity in liver and spleen, mediating significant reversal of the pathological progression in an aggressive preclinical model of LAL-D. In vivo, the new formulation also promoted a more sustained and quantitatively higher LAL expression. In addition, repeated administration regimen mitigated hepatosplenomegaly, and targeted lipidomic analysis revealed strong diminution of CEs and TGs and of toxic lipid species in the liver and spleen. Transcriptomic analysis showed significant attenuation of inflammatory processes, fibrosis and several pathological pathways associated to LAL-D. These findings provide strong evidence that the intracellular production of LAL via mRNA-LNP is a very promising approach for the chronic treatment of LAL-D and support the clinical translation of mRNA therapy to overcome the challenges associated with traditional enzyme replacement therapies. One Sentence Summary Screening of a mRNA-LNPs library yielded a formulation with outmost potency and mitigated the progression of LAL deficiency in a preclinical model.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.256
Teacher spread0.234 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2024
Admission routes2
Has abstractyes

Explore more

Same venuebioRxiv (Cold Spring Harbor Laboratory)Same topicCalcium signaling and nucleotide metabolismFrench-language works237,207